MyFinsight
Home
Blog
About
Inventories
$32,292K
(52.82%↑ Y/Y)
Cash and cash
equivalents
$27,420K
(53.23%↑ Y/Y)
Accounts receivable
$16,503K
(74.76%↑ Y/Y)
Short-term bank deposits
$13,236K
(-14.62%↓ Y/Y)
Other assets
$2,049K
(35.43%↑ Y/Y)
Restricted deposit
$720K
Total current assets
$92,220K
(40.83%↑ Y/Y)
Operating lease right of
use assets
$8,175K
(63.60%↑ Y/Y)
Property and equipment,
net
$5,467K
(15.19%↑ Y/Y)
Deferred income tax asset
$2,374K
(-13.29%↓ Y/Y)
R&d grant
receivable
$2,100K
Total assets
$110,336K
(40.58%↑ Y/Y)
Total liabilities and
stockholders' equity
$110,336K
(40.58%↑ Y/Y)
Stockholders' equity
$71,404K
(43.09%↑ Y/Y)
Total liabilities
$38,932K
(36.21%↑ Y/Y)
Total current
liabilities
$31,391K
(30.30%↑ Y/Y)
Total long-term
liabilities
$7,541K
(67.88%↑ Y/Y)
Other
$23,219K
(45.76%↑ Y/Y)
Trade
$6,506K
(-2.74%↓ Y/Y)
Operating lease
liabilities
$1,666K
(13.18%↑ Y/Y)
Operating lease
liabilities
$7,541K
(94.51%↑ Y/Y)
Back
Back
Balance Sheet
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)
source: myfinsight.com